Evidence map›Paper›PMID 38097113›Full record

Observational studyJournal of hepatology2024

Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis.

Silvia Nardelli, Oliviero Riggio, Fabio Marra, Stefania Gioia, Dario Saltini, Daniele Bellafante, Valentina Adotti, Tomas Guasconi, Lorenzo Ridola, Martina Rosi and 9 more

Open access · hybridAbstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. [Research advances on hepatic encephalopathy following transjugular intrahepatic portosystemic shunt].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Silvia NardelliDepartment of Translational and Precision Medicine, Sapienza University of Rome, Italy. Electronic address: nardelli.silvia@gmail.com.
Oliviero RiggioDepartment of Translational and Precision Medicine, Sapienza University of Rome, Italy.
Fabio MarraDepartment of Experimental and Clinical Medicine, University of Florence, Italy.
Stefania GioiaDepartment of Translational and Precision Medicine, Sapienza University of Rome, Italy.
Dario SaltiniDivision of Gastroenterology, Modena Hospital, University of Modena and Reggio Emilia, Modena, Italy.
Daniele BellafanteDepartment of Translational and Precision Medicine, Sapienza University of Rome, Italy.
Valentina AdottiDepartment of Experimental and Clinical Medicine, University of Florence, Italy.
Tomas GuasconiDivision of Gastroenterology, Modena Hospital, University of Modena and Reggio Emilia, Modena, Italy.
Lorenzo RidolaDepartment of Translational and Precision Medicine, Sapienza University of Rome, Italy.
Martina RosiDepartment of Experimental and Clinical Medicine, University of Florence, Italy.
Cristian CaporaliDepartment of Radiology, Modena Hospital, University of Modena and Reggio Emilia, Modena, Italy.
Fabrizio FanelliInterventional Radiology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Davide RoccarinaDepartment of Experimental and Clinical Medicine, University of Florence, Italy.
Marcello BianchiniDivision of Gastroenterology, Modena Hospital, University of Modena and Reggio Emilia, Modena, Italy.
Federica IndultiDivision of Gastroenterology, Modena Hospital, University of Modena and Reggio Emilia, Modena, Italy.
Alessandra SpagnoliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Italy.
Manuela MerliDepartment of Translational and Precision Medicine, Sapienza University of Rome, Italy.
Francesco VizzuttiDepartment of Experimental and Clinical Medicine, University of Florence, Italy.
Filippo SchepisDivision of Gastroenterology, Modena Hospital, University of Modena and Reggio Emilia, Modena, Italy.
Sapienza University of Rome · ITUniversity of Modena and Reggio Emilia · ITUniversity of Florence · ITAzienda Ospedaliero-Universitaria Careggi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsOvert hepatic encephalopathy (OHE) is a major complication of transjugular intrahepatic portosystemic shunt (TIPS) placement, given its high incidence and possibility of refractoriness to medical treatment. Nevertheless, the impact of post-TIPS OHE on mortality has not been investigated in a large population.

methodsWe designed a multicenter, non-inferiority, observational study to evaluate the mortality rate at 30 months in patients with and without OHE after TIPS. We analyzed a database of 614 patients who underwent TIPS in three Italian centers and estimated the cumulative incidence of OHE and mortality with competitive risk analyses, setting the non-inferiority limit at 0.12.

resultsDuring a median follow-up of 30 months (IQR 12-30), 293 patients developed at least one episode of OHE. Twenty-seven (9.2%) of them experienced recurrent/persistent OHE. Patients with OHE were older (64 [57-71] vs. 59 [50-67] years, p <0.001), had lower albumin (3.1 [2.8-3.5] vs. 3.25 [2.9-3.6] g/dl, p = 0.023), and had a higher prevalence of pre-TIPS OHE (15.4% vs. 9.0%, p = 0.023). Child-Pugh and MELD scores were similar. The 30-month difference in mortality between patients with and without post-TIPS OHE was 0.03 (95% CI -0.042 to 0.102). Multivariable analysis showed that age (subdistribution hazard ratio 1.04, 95% CI 1.02-1.05, p <0.001) and MELD score (subdistribution hazard ratio 1.09, 95% CI 1.05-1.13, p <0.001), but not post-TIPS OHE, were associated with a higher mortality rate. Similar results were obtained when patients undergoing TIPS for variceal re-bleeding prophylaxis (n = 356) or refractory ascites (n = 258) were analyzed separately. The proportion of patients with persistent OHE after TIPS was significantly higher in the group of patients who died. The robustness of these results was increased following propensity score matching.

conclusionEpisodic OHE after TIPS is not associated with mortality in patients undergoing TIPS, regardless of the indication. IMPACT AND IMPLICATIONS: Overt hepatic encephalopathy (OHE) is a common complication in patients with advanced liver disease and it is particularly frequent following transjugular intrahepatic portosystemic shunt (TIPS) placement. In patients with cirrhosis outside the setting of TIPS, the development of OHE negatively impacts survival, regardless of the severity of cirrhosis or the presence of acute-on-chronic liver failure. In this multicenter, non-inferiority, observational study we demonstrated that post-TIPS OHE does not increase the risk of mortality in patients undergoing TIPS, irrespective of the indication. This finding alleviates concerns regarding the weight of this complication after TIPS. Intensive research to improve patient selection and risk stratification remains crucial to enhance the quality of life of patients and caregivers and to avoid undermining the positive effects of TIPS on survival.

Indexed as

Esophageal and Gastric VaricesHepatic EncephalopathyPortasystemic Shunt, Transjugular IntrahepaticGastrointestinal HemorrhageHemorrhageHumansLiver CirrhosisQuality of LifeTreatment Outcomeliver cirrhosisovert hepatic encephalopathyportal hypertensionTIPS

Identifiers

PMID38097113
OpenAlexW4389640716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.